Riboscience LLC

Riboscience Presents Phase 1a/b Overall Survival Data for ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination Therapy in Advanced Solid Tumors and Late-Line CRC

Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins…